Takeda Applies For MHLW Approval For Type 2 Diabetes Drug Alogliptin
This article was originally published in PharmAsia News
Takeda applied for new drug approval for type 2 diabetes drug SYR-322 (alogliptin) Sept. 29 with Japan's Ministry of Health, Labor and Welfare. Developed by Takeda San Diego, a Takeda subsidiary created by the company's acquisition of U.S. bioventure company Syrrx, alogliptin is a dipeptidyl peptidase-4 inhibitor. Takeda submitted the NDA application without conducting a domestic Phase III trial in Japan. If approved, Takeda expects alogliptin to be the third major diabetes drug from the company after Actos (pioglitazone) and Basen (voglibose). (Click here for more - Japanese language
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.